Intimation of resignation of Dr. Sanjay Chaturvedi, CEO of Apitoria Pharma Private Limited, wholly owned subsidiary of the Company.

Ceo ResignedManagement Changes View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.0%Reaction day

₹1374.90

prior close

₹1373.90

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.1%+3.9% vs market

Pharmaceuticals peers, median of 163sector-0.1%+4.1% vs sector

On the reaction day the stock moved 3.9 pts more than Nifty Midcap 150 and 4.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

+0.3

15m

+0.4

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.0+0.1+3.9-0.1+4.1

Next day

+7.8+1.8+6.0+1.5+6.3

+7.6+2.9+4.7+2.4+5.2

+8.0+2.8+5.2+2.9+5.2

+7.6+1.7+5.9+2.8+4.8

+8.4-0.9+9.3+0.2+8.2

+9.4+0.9+8.5+1.3+8.1

15d

+6.0+2.9+3.1+2.8+3.2

+6.0+0.4+5.6+1.5+4.6

+16.0+3.7+12.3+5.7+10.2

+17.5+5.6+11.8+7.4+10.1

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma has announced the resignation of Dr. Sanjay Chaturvedi as Chief Executive Officer of Apitoria Pharma Private Limited, its wholly owned subsidiary. Dr. Chaturvedi cited moving on to a different opportunity as the reason for his departure. He has been relieved from services effective close of business hours on May 4, 2026. The company has informed stock exchanges about this change as per regulatory requirements. The filing was signed by Company Secretary B. Adi Reddy.

Likely market impact

The resignation of a subsidiary CEO is relatively minor for Aurobindo Pharma shareholders, as it does not affect the parent company's top leadership. However, it signals some management transition at the subsidiary level and investors may watch for the appointment of a replacement.